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Chikungunya virus recently caused large outbreaks world-wide. In this issue of Cell, Fox et al.
describe several potently neutralizing antibodies against multiple alphaviruses. The structure of
the virus in complex with one of the antibodies reveals the antibody-induced rearrangement and
crosslinking of the viral surface proteins that result in neutralization.The alphavirus Chikungunya virus
(CHIKV) was originally isolated in Africa.
Although it caused sporadic large out-
breaks in Africa, it largely flew under the
scientific radar. In 2004, CHIKV emerged
as a global pathogen when it generated
a much larger pandemic of millions of
cases and a number of deaths in countries
around the Indian Ocean (Schwartz and
Albert, 2010). CHIKV was first reported
in the Americas in 2013 and since then
has spread rapidly in the New World,
with more than a million cases in at least
43 countries, including the United States
(Johansson, 2015). CHIKV is transmitted
by mosquito vectors, and the emergence
of this pathogen has been fueled by its
adaptation to new mosquito species and
by the spread of these vectors into new
areas. CHIKV causes fever and arthritis,
with resultant joint problems that can
linger for years. There are currently no
licensed vaccines or antiviral therapies
for CHIKV or for other alphavirus patho-
gens, including Eastern and Western
equine encephalitis viruses. Those two vi-
ruses are endemic in the United States,
where they cause low numbers of cases
but have high fatality rates. A better un-
derstanding of the immune response
against the array of alphavirus pathogens
would promote the development of
necessary vaccines and immunothera-
peutics. Given the high mutation rate of
RNA viruses, broadly reactive antibody
strategies may be of particular impor-
tance.
In this issue of Cell, a multidisciplinary
team of investigators led by MichaelDiamond screened a panel of mouse
and human monoclonal antibodies raised
against CHIKV and found that, of the 60
that neutralized CHIKV, 19 also bound to
other alphaviruses such as the African
O’nyong’nyong virus (86% identical to
CHIKV) and South American Mayaro virus
(60% identical to CHIKV), with differing
abilities to neutralize these disparate vi-
ruses (Fox et al., 2015). The most potent
of these broadly reactive mAbs, termed
CHK-265, also protected mice from
CHIKV, O’nyong’nyong, andMayaro virus
challenge.
Alphaviruses are small enveloped vi-
ruses with highly organized structures
and infect host cells by receptor-medi-
ated endocytosis and low-pH-triggered
membrane fusion (Kuhn, 2013). On the
surface are two transmembrane glyco-
proteins, the class II fusion protein E1
and the receptor-binding protein E2.
These proteins are arrayed symmetrically
on the viral surface to form 80 spikes,
each a trimer of E2-E1 heterodimers. E2
has three domains with immunoglobulin-
like folds: a central domain A, a distal
domain B, and a membrane-proximal
domain C. E2 covers much of the E1 pro-
tein on the viral surface and clamps the
fusion loop at the membrane-distal tip of
E1 between its domains A and B. E2 reg-
ulates E1’s fusion activity, and a key step
in fusion is the low-pH-triggered dissocia-
tion/rearrangement of the E2-E1 dimer,
thus allowing E1 to insert into the endo-
some membrane and refold to the hairpin
conformation that drives fusion (Gibbons
et al., 2004). A first step in this processCell 163, Nois the ‘‘uncapping’’ of the E1 fusion loop
by the movement of the E2 B domain (Li
et al., 2010; Voss et al., 2010). E2 is the
principal target of neutralizing antibodies,
which have been mapped to locations
across its outer surface, while the E2 A
and B domains are implicated in receptor
interaction (reviewed in Voss et al., 2010).
Here, Fox et al., perform cryoelectron
microscopy on CHK-265 Fabs in com-
plex with virus particles. The resulting
structures illustrate that binding of this
potent neutralizing antibody occurs with
a concomitant structural rearrangement
of the envelope proteins.
CHK-265 is primarily directed toward
domain B of the E2 protein, and binding
of the antibody induces a slight rotation
of domain B from its unbound position.
Unexpectedly, binding of CHK-265 also
causes a concomitant large repositioning
of domain A up and out of each envelope
trimer, involving a 20 A˚ translation and
70 rotation about E1 (Figure 1). Ultimately,
each copy of CHK-265 bridges domain B
of one spike to domain A of a neighboring
trimer on the viral surface, with each Fab
binding 19 residues of domain B and4 res-
iduesof theneighboring trimer’sdomainA.
The effect of CHK-265 binding is a cross-
linking network across the virus surface.
Fab fragments of CHK-265 were less
potent than IgG, suggesting that the IgG
could induce additional cross-linking and
perhaps a steric blockage of viral entry
as well.
Although the orientation of domain A is
changed radically, E2’s receptor-binding
activity is unchanged. Notably, CHIKV stillvember 19, 2015 ª2015 Elsevier Inc. 1053
Figure 1. Antibody-Induced Rearrangements of Chikungunya Virus Envelope Proteins
(A) Binding of Fab CHK-265 induces a rearrangement of domains A and B of envelope protein E2. The rest of E2 and the E1 protein are both colored as a single
gray oval for simplicity. Illustrated is one monomer. White lines represent the axes of major b strands in the domain structure.
(B) Domain rotation illustrated for an envelope trimer, before and after binding of Fab CHK-265.
(C) Fab CHK-265 bridges domain A of one copy of E2 to domain B of a different copy of E2 belonging to a neighboring trimer. Figure: Christina Corbaci, TSRI.attaches to cells in the presence of CHK-
265, so the block achieved by this anti-
body is not at receptor engagement but,
rather, at events downstream. CHK-265
partially inhibits virus fusion and partially
inhibits egress: its total dampening of
infectivity may result from a sum of sepa-
rate functions at separate steps. Based
on the structure, CHK-265 could function
by inhibiting the uncapping step by
domain B or by ‘‘clamping’’ the E2-E1
dimer to impede its dissociation. Alterna-
tively, antibody-mediated crosslinking of
adjacent spikes could inhibit more global
rearrangements of the virus particle
surface that occur during fusion, as has
been previously observed for West Nile
virus (Kaufmann et al., 2010).
Unlike viruses with structurally related
fusion proteins, such as Dengue virus,
there is to date no compelling evidence
that antibodies to the alphavirus enve-
lope proteins cause antibody-dependent
enhancement of infection. Vaccine candi-1054 Cell 163, November 19, 2015 ª2015 Elsdates, including those based on virus-
like particles, measles virus chimeras, or
attenuated CHIKV, are under develop-
ment (reviewed in Cassone, 2015;Weaver
et al., 2012). The correlations shown in
this paper between broadly neutralizing
CHIKV antibodies and the structure of
the epitopes on the viral particle may
prove important to developing and
evaluating these vaccines. While the
CHIKV antibodies discussed here did
not cross-neutralize the single encepha-
litic alphavirus tested, development of a
potent neutralizing antibody could be an
important strategy against these viruses
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